#EASD24: Weight loss readouts from Novo Nordisk, Boehringer Ingelheim,...
Companies large and small are set to present data on their next-generation weight loss drug candidates at the European Association for the Study of Diabetes annual meeting in Madrid, Spain. The...
View ArticleJ&J and Legend say Carvykti improved survival in earlier-line multiple myeloma
In a late-stage study, Johnson & Johnson and Legend Biotech’s CAR-T therapy Carvykti improved survival in multiple myeloma patients who had received one to three prior lines of therapy compared to...
View ArticleCheckpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection
Checkpoint Therapeutics is taking a second shot at approval for its anti-PD-L1 candidate after the FDA rejected its first submission around seven months ago due to issues at a third-party manufacturer....
View ArticleFollowing a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot
Last week, Ovid Therapeutics disclosed layoff plans in an SEC filing following a Phase 3 flop for its Takeda-partnered epilepsy program. The news sent its stock price $OVID down 70%. Ovid has been here...
View ArticleYuhan, Ubix ink licensing deal; Xenpozyme's royalty deal
Plus, news about Ipsen, Exelixis, Innovent, Codexis, Crosswalk Therapeutics and J&J: Yuhan licenses prostate cancer drug: The biotech will pay Seoul-based Ubix Therapeutics $3.6 million upfront and...
View ArticleClik here to view.
Moderna wins $176M BARDA award to finance bird flu work
Moderna received a significant boost from the federal government, snagging a $176 million contract to help advance a bird flu vaccine. The award, which was granted by the Biomedical Advanced Research...
View ArticleAs confidence falls, biopharma companies take precautions with Chinese...
Geopolitical tensions and threats of decoupling have led to a steep decline in American companies’ confidence in working with Chinese partners, although few have taken steps to end relationships,...
View Article'Optimizing R&D structure is also on the horizon, without exception,' new...
Sumitomo Pharma CEO Toru Kimura says that he sees the need to streamline the company’s business and product lineup, and is considering steps including job cuts. He’s also looking at how to optimize the...
View ArticleEli Lilly wins long-awaited approval for Alzheimer’s drug
After decades of trying to develop a treatment for Alzheimer’s disease, Eli Lilly has finally won FDA approval for its drug donanemab, which will be marketed as Kisunla. An approval was originally...
View ArticleLondon court upholds Moderna patent in vaccine dispute with Pfizer, but...
Moderna’s long-running patent dispute with Pfizer and BioNTech intensified Tuesday after London’s High Court of Justice upheld one of Moderna’s key mRNA patents, but invalidated another. The court...
View ArticleEmergent announces $250M in contract modifications from the US
Emergent BioSolutions scored more than $250 million in government contract modifications for four medical countermeasures, including anthrax, smallpox and botulism vaccines. As part of the contract,...
View ArticleClik here to view.
GSK licenses full rights to CureVac’s flu, Covid mRNA vaccines for $429M in...
GSK is handing mRNA vaccine partner CureVac €400 million ($429 million) upfront to take over full rights to the influenza and Covid vaccine candidates they have been collaborating on, while walking...
View ArticleClik here to view.
Beacon raises $170M to take on J&J in ocular gene therapy
Transatlantic biotech Beacon Therapeutics has raised $170 million to potentially bring a rare ophthalmology gene therapy to market in a competition with Johnson & Johnson. J&J is ahead of...
View ArticleClik here to view.
Flagship appears to boost target of eighth fund by up to $500M
Flagship Pioneering, the sprawling life sciences investor and startup incubator, appears to be seeking more capital than originally planned for its eighth fund. The Boston-area firm is raising up to...
View ArticleSanofi and Regeneron’s Dupixent wins EU nod in COPD ahead of September PDUFA
Sanofi and Regeneron’s Dupixent has notched another indication in the EU, this time for a common lung disease, marking the first-ever targeted therapy for the condition in the region. The French...
View ArticleClik here to view.
Pfizer adds ex-State Street CEO to the board; Two Merus execs head for the exit
A few comings and goings before the Independence Day holiday in the US: Cyrus Taraporevala → Pfizer has welcomed former State Street Global Advisors president and CEO Cyrus Taraporevala to the board of...
View ArticleApollomics plans to lay off staff, narrow focus for lung cancer trial
Apollomics is making major cost cuts and leadership changes to stay afloat. The oncology biotech announced Wednesday morning that co-founder and president Sanjeev Redkar and chief medical officer Peony...
View ArticleClik here to view.
In biotech's uneven recovery, 50 startups raised megarounds in first half of...
The list of nine-figure financings for private biotechs is starting to look like the scrolling receipts from CVS or Walgreens. If that pace continues, it could top the heydays of 2020 and 2021. In the...
View ArticleMississippi judge rejects efforts by Novartis, PhRMA to block 340B state law
A Mississippi federal judge has denied efforts by Novartis and industry trade group PhRMA to thwart a state law that would keep drugmakers from imposing some restrictions around the federal drug...
View ArticleExperts want to make it easier to get RSV vaccines. Did they make it harder...
Last week, experts on the CDC’s panel that sets vaccine recommendations created new guidance for who should get RSV shots heading into the second-ever season of vaccination for the respiratory disease....
View Article